Recombinant Japanese fire-bellied newt Annexin-5 protein, His-tagged

• Cat.No.: Annexin-5-5343J
• Product Overview: Recombinant Japanese fire-bellied newt Annexin-5 protein(P70075)(1-323aa), fused to N-terminal His tag, was expressed in Yeast.

Specification

• Source: Yeast
• Species: Japanese fire-bellied newt
• Tag: His
• Form: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Molecular Mass: 30.3 kDa
• Protein length: 1-323aa
• Purity: Greater than 90% as determined by SDS-PAGE.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%.

Reviews

09/08/2021

As a researcher, utilizing Annexin-5 protein in trials offers numerous advantages that contribute to the successful completion of experiments and the acquisition of valuable data.

06/03/2021

manufacturers offer customization options, such as alternative conjugation methods or tailored formulations, allowing researchers to optimize Annexin-5 protein to their specific experimental needs.

04/21/2021

When combined with the support and quality assurance provided by the manufacturer, researchers can confidently utilize Annexin-5 protein to unravel the intricate mechanisms underlying cellular processes, ultimately advancing scientific knowledge.

09/26/2020

Annexin-5, a calcium-dependent phospholipid-binding protein, plays a crucial role in various cellular processes, making it a valuable tool for investigation.

08/27/2017

This ensures the consistency and reproducibility of experimental results, promoting confidence in the obtained data.

Q&As

Have there been any studies on Annexin-5 in autoimmune disorders?

Yes, Annexin-5 has been studied in the context of autoimmune disorders. Autoimmune diseases involve dysregulated immune responses that can lead to tissue damage and inflammation. Annexin-5's involvement with phosphatidylserine and apoptotic cell clearance has raised interest in its potential role in autoimmune disorders. Studies have shown altered Annexin-5 levels or function in conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). For example, Annexin-5 deficiency has been implicated in the development of antiphospholipid syndrome, an autoimmune disorder characterized by the presence of antibodies against phospholipids and associated with increased risk of blood clots. However, more research is needed to further elucidate the role of Annexin-5 in autoimmune disorders and its potential as a therapeutic target.

Can Annexin-5 be used as a predictive or prognostic marker in diseases?

Annexin-5 expression has been studied as a potential biomarker in various diseases. For example, altered Annexin-5 levels have been associated with cancer progression and prognosis. Lower levels of Annexin-5 have been observed in certain cancers, while higher levels have been linked to poor outcomes in others. Additionally, Annexin-5 expression changes have been reported in cardiovascular diseases and autoimmune disorders, suggesting its potential as a predictive or prognostic marker. However, more research is needed to validate these findings.

Are there any known interactions or binding partners for Annexin-5 protein?

Yes, Annexin-5 can interact with several other proteins and molecules. Besides its binding to phosphatidylserine (PS), Annexin-5 has been reported to interact with actin, cytoskeletal components, ion channels, and other annexin family members. It can also associate with certain proteins involved in calcium signaling and apoptosis, such as caspases and Bcl-2 family members.

Are there any known drug interactions with Annexin-5?

As of my knowledge cutoff date, there are no widely reported drug interactions specifically associated with Annexin-5. However, the potential for drug interactions should always be considered when using any therapeutic agent. It is important to consult with healthcare professionals or refer to drug interaction databases to identify any potential interactions with specific drugs.

Does Annexin-5 have any diagnostic applications?

Yes, Annexin-5 has diagnostic applications, particularly in the field of nuclear medicine. Annexin-5 labeled with a radioactive tracer, such as Technetium-99m (99mTc), can be used in single photon emission computed tomography (SPECT) imaging to detect apoptosis or evaluate cell death in various tissues. This technique has been explored for diagnosing and monitoring conditions like myocardial ischemia, cancer, and neurodegenerative disorders.

Can Annexin-5 be used for diagnostic purposes?

Yes, Annexin-5 can be used for diagnostic purposes in certain applications. The ability of Annexin-5 to bind to phosphatidylserine on the surface of apoptotic cells has been utilized for imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). In these techniques, Annexin-5 is labeled with a radioactive tracer, allowing for the visualization and quantification of apoptosis in various tissues. This can be useful for diagnosing and monitoring diseases such as cancer, stroke, and cardiovascular disorders. Additionally, Annexin-5 has been explored as a potential biomarker for certain conditions, with altered levels or expression observed in diseases like preeclampsia and rheumatoid arthritis.

Can Annexin-5 be used as a therapeutic agent?

Yes, Annexin-5 has shown potential as a therapeutic agent in various preclinical and clinical studies. Its ability to bind to PS on apoptotic cells has been utilized in targeted drug delivery strategies. By conjugating therapeutic agents to Annexin-5, it is possible to specifically deliver drugs to apoptotic cells or sites of inflammation. Annexin-5 has also been investigated as a potential treatment for conditions involving excessive blood clotting, as it can inhibit clotting factors from binding to PS on activated platelets.

Can Annexin-5 be used in the treatment of cancer?

Annexin-5 has shown potential for anticancer therapy in preclinical studies. It can be used as a vehicle for targeted drug delivery to apoptosis-sensitive cancer cells, as these cells typically expose phosphatidylserine on their surface. By conjugating anticancer drugs or therapeutic agents to Annexin-5, it is possible to specifically target and kill cancer cells while minimizing toxicity to healthy cells. Some studies have also explored the use of Annexin-5 as a therapeutic protein itself, as it can induce apoptosis in cancer cells through its intrinsic properties.

What are the potential side effects or risks associated with using Annexin-5 therapeutically?

The potential side effects or risks of using Annexin-5 therapeutically can vary depending on the specific context of its application. As a protein-based therapeutic agent, there is a potential risk of immunogenicity, where the body's immune system could develop an immune response against Annexin-5. However, this can be mitigated by using purified or recombinant versions of Annexin-5 that have been modified to reduce immunogenicity. Other potential risks can include off-target effects, such as unintended binding to normal cells that also expose phosphatidylserine, and potential interactions with other proteins or molecules that could lead to adverse effects. Comprehensive preclinical and clinical studies are necessary to assess the safety and potential side effects of using Annexin-5 therapeutically.

How does Annexin-5 protein interact with phosphatidylserine (PS)?

Annexin-5 has a high affinity for PS, which is exposed on the cell membrane during apoptosis or in response to cellular stress. The calcium-dependent binding of Annexin-5 to PS allows it to coat the membrane, preventing clotting factors from binding to PS and reducing inflammation. Annexin-5 acts as a bridge between PS on apoptotic cells and phagocytic cells, facilitating the clearance of apoptotic cells by macrophages.

Is Annexin-5 involved in neurodegenerative diseases?

There is some evidence suggesting a potential role for Annexin-5 in neurodegenerative diseases. Annexin-5 has been found to bind to β-amyloid fibrils, which are a hallmark of Alzheimer's disease. It is thought that Annexin-5 may be involved in the clearance of β-amyloid plaques from the brain. However, the exact mechanisms and implications of this interaction are still not fully understood, and further research is required to elucidate the role of Annexin-5 in neurodegenerative diseases.

Where is Annexin-5 protein found in the body?

Annexin-5 is widely expressed in various tissues and cell types. It is found in both intracellular and extracellular compartments. Intracellularly, it can be localized to the plasma membrane, cytoplasm, and nucleus, depending on the cellular context. Extracellularly, it can be present in body fluids and on the surface of cells.

Can Annexin-5 be used for therapeutic purposes in cardiovascular diseases?

Annexin-5 has been investigated as a potential therapeutic agent in cardiovascular diseases. It has been studied for its ability to inhibit blood clot formation by binding to phosphatidylserine on activated platelets, thereby preventing the binding of clotting factors. Additionally, Annexin-5 has been evaluated for its role in reducing reperfusion injury in conditions like myocardial infarction by modulating apoptosis and inflammation. While the potential therapeutic applications of Annexin-5 in cardiovascular diseases are promising, further research is needed to fully understand its mechanisms and efficacy in different cardiovascular conditions.

Can Annexin-5 be used in the treatment of neurodegenerative diseases?

Annexin-5 has been investigated as a potential therapeutic agent in neurodegenerative diseases. It has been studied for its involvement in interactions with amyloid proteins, which are a hallmark feature of diseases like Alzheimer's and Parkinson's. Annexin-5's ability to bind to these proteins may have implications for their clearance or aggregation.

Are there any diseases associated with Annexin-5 protein?

Annexin-5 has been implicated in various disease processes. For example, altered Annexin-5 expression has been observed in cancer, cardiovascular diseases, and autoimmune disorders. Annexin-5 has also been investigated as a potential diagnostic and prognostic marker in some diseases. However, further research is needed to fully understand the role of Annexin-5 in these conditions and its potential as a therapeutic target.

Are there any ongoing clinical trials involving Annexin-5?

As of my knowledge cutoff date, there have been clinical trials involving Annexin-5. These trials have explored the use of Annexin-5 in various applications, including imaging of apoptosis in cancer patients, assessing myocardial viability in cardiac patients, and evaluating renal function in kidney transplant recipients. However, the availability of ongoing clinical trials may vary, and it is recommended to consult resources such as clinical trial registries or scientific databases for the most up-to-date information on Annexin-5 clinical trials.

Is Annexin-5 used in medical or research applications?

Yes, Annexin-5 is widely used in medical and research applications. It is often employed in laboratory techniques for detecting apoptotic cells, as it can selectively bind to PS on the surface of these cells. Annexin-5 is labeled with fluorescent dyes or radioactive tracers to visualize and quantify apoptotic cells in research studies or diagnostic assays. Additionally, Annexin-5-based imaging approaches are used in medical imaging, such as in detecting ischemic heart disease and evaluating blood clot formation.